Curis Inc CRIS:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/05/21 EST
9.47quote price arrow up+0.34 (+3.72%)
Volume
1,872,735
52 week range
0.62 - 13.44

...

Loading . . .

KEY STATS

  • Open9.07
  • Day High9.54
  • Day Low8.25
  • Prev Close9.47
  • 52 Week High13.44
  • 52 Week High Date01/19/21
  • 52 Week Low0.62
  • 52 Week Low Date04/07/20
  • Market Cap779.48M
  • Shares Out82.31M
  • 10 Day Average Volume1.39M
  • Dividend-
  • Dividend Yield-
  • Beta3.10
  • 1 Year % Change682.64

RATIOS/PROFITABILITY

  • EPS (TTM)-0.82
  • P/E (TTM)-11.54
  • Fwd P/E (NTM)-27.45
  • EBITDA (MRQ)-25.813M
  • ROE (MRQ)-8,594.04%
  • Revenue (MRQ)11.10M
  • Gross Margin (MRQ)95.11%
  • Net Margin (MRQ)-279.32%
  • Debt To Equity (MRQ)-3.11%

EVENTS

  • Earnings Date03/17/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Curis Inc News

There is no recent news for this security.

Latest CRIS News From Our Partners

QUOTE FINDER

Profile

MORE
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed...
Martyn Greenacre
Chairman
James Dentzer
President
William Steinkrauss CPA
Chief Financial Officer
Address
128 SPRING STREET, BUILDING C, SUITE 500
Lexington, MA
02421
United States